Filing Details

Accession Number:
0001209191-19-023887
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-04-05 18:57:22
Reporting Period:
2019-04-03
Accepted Time:
2019-04-05 18:57:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
879407 Arrowhead Pharmaceuticals Inc. ARWR Pharmaceutical Preparations (2834) 460408024
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1423029 Richard Christopher Anzalone 225 S. Lake Avenue
Suite 1050
Pasadena CA 91101
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-04-03 50,000 $19.30 2,092,455 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.30 to $19.31, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
  2. Includes a total of 933,333 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole.